Acute Lymphobkastic LeukemiaNCT07245251

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

A study testing STR-P004 in people with Acute Lymphobkastic Leukemia, run by Starna Therapeutics.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Trial summary

This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Acute Lymphobkastic Leukemia
What is being tested?: STR-P004
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 11 participants
Where: No sites listed yet
Study dates: 3 Dec 2025to 30 Dec 2026
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Subjects with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia who currently have poor prognosis treatment options:
Patients voluntarily sign the informed consent form;
Age between 18 and 65 years, regardless of gender;
Diagnosed with B-cell acute lymphoblastic leukemia and meeting any of the following conditions:
(1) Relapse: Relapse within 12 months after first remission following standard treatment;
(2) Refractory:

Show all 23Show fewer

No remission after ≥6 weeks of induction therapy or two courses of induction therapy;
Relapse after ≥2 complete remissions (CR) or CR with incomplete hematologic recovery (CRi);
First relapse after chemotherapy, with no remission after at least one salvage therapy;
d) Relapse after autologous or allogeneic hematopoietic stem cell transplantation;
Within 3 months before screening, bone marrow or peripheral blood tests show leukemia cells expressing CD19;
For Ph+ ALL patients, treatment failure with at least two tyrosine kinase inhibitors (TKIs) (including at least one second-generation TKI) or intolerance to TKI therapy; if the patient has a T315I mutation, TKI salvage therapy is not required;
During screening, the proportion of bone marrow blasts and immature lymphocytes is ≥5%;
Hemoglobin ≥60 g/L, platelets ≥30 × 10^9/L;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Adequate organ function, meeting the following criteria:
Aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN);
Alanine aminotransferase (ALT) ≤3 × ULN;
Total serum bilirubin ≤2 × ULN, unless combined with Gilbert's syndrome; patients with Gilbert's syndrome may be included if total serum bilirubin ≤3.0 × ULN and direct bilirubin ≤1.5 × ULN;
Serum creatinine ≤2.0 × ULN or creatinine clearance ≥60 mL/min (Cockcroft and Gault formula);
Minimum lung reserve: defined as ≤ grade 1 dyspnea and oxygen saturation >91% without oxygen supplementation;
International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN;
Women of childbearing potential must have a negative blood/urine pregnancy test during screening and within 3 days before dosing. Any patient with reproductive potential must agree to use effective contraception throughout the study and for at least 2 years after the last dose of study treatment. As judged by the investigator, patients are considered to have reproductive potential if they are biologically capable of having children and have normal sexual activity. Female patients without reproductive potential (i.e., meeting at least one of the following criteria): hysterectomy, bilateral oophorectomy, bilateral tubal ligation, medically confirmed ovarian failure, or medically confirmed menopause (≥12 consecutive months of amenorrhea).

Who cannot join

Subjects meeting any of the following criteria cannot be enrolled:
Active central nervous system (CNS) leukemia (patients with CNS disease symptoms must undergo lumbar puncture to exclude CNS leukemia);
Isolated extramedullary relapse;
Prior CAR-T therapy or other genetically modified cell therapy within 6 months before screening;
Chemotherapy within 2 weeks before dosing, except for the following:
1.

Show all 24Show fewer

Pre-treatment chemotherapy as specified in the protocol;
TKI and hydroxyurea must be discontinued 72 hours before cell infusion;
6-mercaptopurine, 6-thioguanine, methotrexate (standard dose), cytarabine (standard dose), vincristine, and asparaginase must be discontinued 1 week before cell infusion;
Intrathecal chemotherapy for CNS leukemia prophylaxis must be discontinued 1 week before cell infusion; 2. Systemic corticosteroid therapy discontinued for less than 72 hours before dosing, except for physiological replacement doses (e.g., prednisone <10 mg/day or equivalent); 3. Acute graft-versus-host disease (GVHD) within 4 weeks before screening or moderate to severe chronic GVHD; systemic medication for GVHD within 4 weeks before dosing; 4. Active systemic autoimmune disease under treatment; 5. Any of the following:
Hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) positive;
Hepatitis B e antibody (HBe-Ab) positive with HBV-DNA copy number above the lower limit of quantification;
Hepatitis C antibody (HCV-Ab) positive;
Anti-Treponema pallidum antibody (TP-Ab) positive;
Human immunodeficiency virus (HIV) antibody positive;
EBV-DNA or CMV-DNA copy number above the lower limit of quantification; 6. History or presence of other malignancies within 5 years before screening, except for those with low risk of recurrence as judged by the investigator after curative treatment and follow-up for more than 5 years; 7. Any of the following cardiac conditions:
Left ventricular ejection fraction (LVEF) ≤45% (ECHO);
New York Heart Association (NYHA) class III or IV congestive heart failure;
Severe arrhythmia requiring treatment or clinically significant conduction abnormalities on ECG, including QTc interval ≥480 ms (QTcB = QT/RR^(1/2));
Uncontrolled hypertension (systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg) or pulmonary hypertension despite standard treatment;
Unstable angina;
Myocardial infarction or coronary artery bypass graft/stent surgery within 6 months before dosing;
Clinically significant valvular disease;
Other cardiac diseases deemed unsuitable for enrollment by the investigator; 8. Clinically significant pleural effusion at screening; 9. History of epilepsy, cerebral ischemia/hemorrhage, cerebellar disease, or other active CNS diseases; 10. History of deep vein thrombosis or pulmonary embolism within 6 months before screening; 11. Known history of hypersensitivity to any component of the study drug; 12. Live vaccination within 6 weeks before screening; 13. Active infection at screening; 14. Expected lifespan less than 3 months; 15. Participation in another interventional clinical study within 3 months before screening involving investigational drugs not yet marketed, or within 5 half-lives for marketed drugs; or intention to participate in another clinical trial or receive anti-tumor therapy outside the protocol during the study; 16. Other conditions deemed unsuitable for participation by the investigator.

About this study

Official title: An Early-Phase Clinical Study Evaluating the Safety and Clinical Efficacy of STR-P004 in Subjects With Relapsed/Refractory CD19-Positive Acute Lymphoblastic Leukemia

Read the detailed description

The study adopts a dose-escalation approach combining "accelerated titration" and "traditional 3+3" design. Five dose-escalation cohorts are planned within the dose range of AA mg/kg to BB mg/kg. The escalation follows a modified Fibonacci sequence (i.e., 2, 1.67, 1.5, 1.4, 1.33, 1.33… multiples), with faster escalation in the early stages to minimize patient exposure to ineffective doses and quickly reach the predicted effective dose range, followed by reduced escalation rates to ensure safety and explore efficacy.

Conditions: Acute Lymphobkastic Leukemia
Being tested: STR-P004
Keywords: STR-P004, ALL

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

STR-P004Drug
This study enrolls adult patients with B-cell acute lymphoblastic leukemia (B-ALL). Enrolled patients receive STR-P004 at the corresponding dose via intravenous infusion, administered four times

Study groups in NCT07245251
Study group	Role	What they receive
Dose	Experimental	Five dose-escalation cohorts are planned within the dose range of AA mg/kg to BB mg/kg. The escalation follows a modified Fibonacci sequence Receives: Drug: STR-P004

What is being measured

The primary outcome is the main question the study is designed to answer.

Safety and tolerability endpoints
Dose-limiting toxicity (DLT), all adverse events (AEs)/serious adverse events (SAEs), and other safety evaluation indicators
Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

3 Dec 202530 Dec 2026

First posted24 Nov 2025
Study start3 Dec 2025 (estimated)
Primary completion2 Nov 2026 (estimated)
Study completion30 Dec 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Acute Lymphobkastic LeukemiaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 11 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07245251
Sponsor's protocol ID: STR-P004-004
Status last verified: Nov 2025
First submitted: 17 Nov 2025
Last updated: 24 Nov 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Interested in taking part?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

Official record

Enrolling by invitationPhase 1/2
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Acute Lymphobkastic Leukemia, B Cell Lymphoma
Not yet recruitingPhase 2
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia
Acute Lymphobkastic Leukemia, Adult
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruitingPhase 1/2
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
B Cell Malignancies, Acute Lymphobkastic Leukemia
RecruitingObservational study
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia

All Acute Lymphobkastic Leukemia trials